Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

FBXW7 expression is associated with prognosis and chemotherapeutic outcome in Chinese patients with gastric adenocarcinoma

  • Mao-Ran Li1,
  • Chun-Chao Zhu1,
  • Tian-Long Ling1,
  • Ye-Qian Zhang1,
  • Jia Xu1,
  • En-Hao Zhao1 and
  • Gang Zhao1Email author
Contributed equally
BMC GastroenterologyBMC series – open, inclusive and trusted201717:60

DOI: 10.1186/s12876-017-0616-7

Received: 3 March 2016

Accepted: 20 April 2017

Published: 2 May 2017

Abstract

Background

FBXW7, a component of the Skp-Cullin1-F-box, mediates target protein recognition. It is a tumor suppressor gene that plays a role in the regulation of cell cycle exit and reentry via c-Myc, c-Jun and Notch degradation. There are few studies, particularly involving a large patient cohort, that have evaluated FBXW7 during gastric cancer progression.

Methods

Our study aimed to evaluate the value of FBXW7 as a clinical marker in gastric adenocarcinoma (GC) patients including a subset treated with postoperative chemotherapy. Quantitative reverse transcription PCR (qRT-PCR) assay was used to measure FBXW7 transcript levels in tumors paired with normal gastric tissue in 24 gastric adenocarcinoma patients. Subsequently, 546 additional GC samples were evaluated from patients that underwent radical gastrectomy, including 118 early stage cases(Stage I) and 428 advanced stage cases (Stages II or III). Amongst the advanced stage patient cases evaluated, 347 received postoperative adjuvant chemotherapy. All 546 gastric adenocarcinoma cases were then evaluated by tissue microarray and immunohistochemistry (IHC) for FBXW7 expression. Clinicopathological features and diagnoses were confirmed by histopathologic evaluation and review of clinical data. Overall survival (OS) was then evaluated in the 546 gastric cancer patients.

Results

By immunohistologic evaluation, low expression of FBXW7 in primary gastric cancer significantly correlated with poor differentiation of tumor cells. Moreover, low FBXW7 expression was associated with worse survival as well as worse adjuvant chemotherapy response.

Conclusion

Our findings suggest that FBXW7 may serve as an important predictor in chemotherapeutic responses.

Keywords

FBXW7 Gastric cancer Prognosis Chemotherapeutic outcome

Background

Gastric cancer is one of the most common worldwide malignancies with an increasing worldwide incidence rate of new cases, currently standing at more than 100 million cases per year. Gastric cancer is more common in China [1, 2] with a morbidity and mortality rate twice that of the worldwide average. Chemotherapy plays a key role in the treatment plan of patients with advanced gastric cancer [3]; however, the occurrence of chemotherapy drug resistance, especially multidrug resistance (MDR),limits its effectiveness [4]. At present, the mechanism of MDR remains unclear.

F-box and WD repeat domain-containing7 (FBXW7), an important member of the F-box family located on chromosome 4q32, was found by Leland while studying the budding yeast cell division cycle [5]. There are three protein isoforms:FBXW7α,FBXW7β and FBXW7γ. FBXW7αis considered the most important subtype as it is widely distributed in the human body. FBXW7 serves as a subunit of the SCF (Skp-Cullin1-F-box) complex [6]. The SCF complex participates in the ubiquitin-proteasome pathway reaction, a three-level cascade degradation of misfolded proteins, and is implicated in tumorigenesis as protein accumulation is thought to play a key role in tumor formation [7]. FBXW7 is widely considered to be an effective tumor suppressor gene [8, 9]. It has been shown that down regulation of FBXW7 can promote tumor cell proliferation. In turn, loss of FBXW7 alters the tumor gene expression profile and leads to increased lung cancer development in a murine model. FBXW7 can target the degradation of MCL1,cyclin E,Notch,c-Jun and c-Myc, cancer genes related to the proliferation and regulation of gastric cancer cells [10, 11]. MCL1 is highly associated with taxol resistance in malignant tumors derived from epithelial cells [12]. At present, FBXW7 down-regulation is found in numerous human malignant tumors, including non-small cell lung cancer, T cells leukemia, bile duct carcinoma, pancreatic carcinoma and endometrial carcinoma [9, 13, 14]. Although some studies indicate that low FBXW7 expression is associated with tumor progression and drug resistance in many malignancies [15, 16], there is a paucity of studies examining FBXW7 in gastric cancer. Therefore, the aim of this study was to explore the relationship between FBXW7 expression and the clinicopathological characteristics as well as chemotherapeutic outcomes in gastric adenocarcinoma patients.

Methods

Patients

Twenty-four freshly collected gastric cancer specimens paired with adjacent normal gastric tissue were obtained from radical gastrectomy surgeries performed from January 2013 to August 2014. Resected cancer and paired noncancerous tissues were immediately frozen in liquid nitrogen, and maintained at -80 °C until RNA and DNA extraction for quantitative real-time PCR was performed.

For FBXW7 immunohistochemical evaluation, GC patient inclusion criteria were as follows: 1) apathologic diagnosis of gastric adenocarcinoma; 2) no radiotherapy, chemotherapy, nor other anti-cancer therapies prior to the surgery; 3) radical tumor resection; 4) availability of complete clinicopathological and clinical follow-up data. The final date of follow-up was 31 December 2014 for all cases examined.

A total of 546 paraffin-embedded tissue samples met the previous criteria and were collected from GC patients at Department of Gastrointestinal Surgery, RenJi Hospital, Shanghai Jiao tong University, School of Medicine from January 2006 to December 2011 for tissue microarray construction and immunohistochemistry staining. Overall survival (OS) is calculated from the date of tumor resection until death.

A cohort of 347 patients underwent postoperative floxuridine-based chemotherapy treatment amongst the 546 GC patients examined. Tumor stage of all 347 patients was TNM stages II and stage III. Within this treated cohort, 84 patients were treated with a regimen including paclitaxel, 66 patients’ regimen included anthracycline, and 261 patients’ regimen included platinum. Dosage of chemotherapeutics per cycle were as follows: 1) docetaxel (Taxotere, Sanofi-Aventis, France) 75 mg/m2, intravenous; 2) oxaliplatin (Exolatin, Laboratoires Thissen, Belgium) 130 mg/m2, intravenous; or cisplatin 60 mg/m2, intravenous; 3) epirubicin (Pharmorubicin, Pfizer, USA) 100 mg/m2, intravenous; 4) fluorouracil 30 mg/kg, maintain 72 h by venous pump D2-D4. All patients with radical operation received adjuvant chemotherapy for 6 cycles for a period of 21 days.

Total RNA extraction and quantitative real-time PCR

Total RNA was extracted from 24 fresh cancer tissue samples and paired normal tissue using Trizol reagent (Takara, Dalian, China) per the manufacturer’s instructions. The reverse-transcription reactions were carried out with random primers and M-MLV Reverse Transcriptase (Takara, Dalian, China) and resulting cDNA used for quantitative real-time PCR reaction via SYBR-Green method. All qPCR reactions were performed on a StepOneTM real-time PCR System (Applied Biosystems, Foster City, CA, USA). The specific primer sequences of FBWX7 and 18 s (18svedberg) were as follow: FBXW7 sense primer 5’-AAAGAGTTGTTAGCGGTTCTCG-3’ and antisense primer 5’-CCACATGGATACCATCAAACTG-3’. 18 s sense primer 5’-TGCGAGTACTCAACACCAACA-3’ and antisense primer 5’-GCATATCTTCGGCCCACA-3’. 18 s was used as an internal control. The 2-ΔCt method was used to quantify the relative FBXW7 expression levels.

Tissue microarrays construction

TMAs were constructed by Shanghai Zhuo Li Biotechnology Co., Ltd (Zhuo Li Biotechnology Co, Shanghai, China). Because gastric cancer tissue is dispersed within gastric interstitial space, GC sample staining is necessary. Consequently, tissue paraffin blocks of GC samples were stained with hematoxylin-eosin to confirm the diagnoses and marked at fixed points with most typical histological characteristics under a microscope. Two 1.5 mm cores per donor block were transferred into a recipient block tissue microarrayer, and each dot array contained fewer than one hundred and sixty dots. Three-micron-thick sections were cut from the recipient block and transferred onto glass slides using an adhesive tape transfer system for ultraviolet cross linkage.

Immunohistochemistry

The tissue microarray glass slides were baked at 55 °C for 1 h, and then de-paraffinized gradually through xylene, 50% xylene, and gradient concentrations of ethanol until immersed in tap water. Tissue sections were blocked for peroxidase activity with 0.3% Hydrogen peroxide at 37 °C for 30mins. Antigen retrieval was carried out via boiling in 10 mmol/L citrate buffer (pH 6.0) for fifteen mins. Then the tissues were incubated with FBXW7 antibody (diluted 1:100;mouse monoclonal anti-FBXW7 antibody [3D1] ab128062, Abcam, USA) overnight at 4 °C. Next day, the tissues were washed with phosphate buffer solution (PBS) for three times and incubated with goat anti-rabbit IgG-HRP (HUABIO) or goat anti-mouse IgG-HRP (ABCAM) secondary antibody for 1 h at room temperature. Immunostaining was carried out using diaminobenzidine substrate chromogen (Dako, Carpinteria, CA, USA) method and chromogenic reaction was controlled under microscope. After immunostaining, tissues were immersed into hematoxylin for nuclear staining. The slides were then dehydrated through gradient concentrations of ethanol, cleared with xylene, and cover slipped with neutral balsam.

TMAs were scored as follows: absence of any staining as score 0; weak-to-strong complete nuclear staining in <25% of tumor cells as score 1; weak-to-strong complete nuclear staining in 25–50% of tumor cells as score 2; strong complete nuclear staining in ≥50% of tumor cells as score 3. Score 0–1 was considered as low expression and a score of 2–3 was high expression for subsequent statistical analyses. All scoring was performed by 2 independent pathologists, who were blinded to clinical outcomes.

Statistical analysis

Statistical analyses were conducted using SPSS 20.0 (SPSS Inc, Chicago, IL, USA) and GraphPad Prism 5 (San Diego, CA) software. FBXW7 mRNA in the cancerous and noncancerous tissues were compared using a paired-samples t test. The chi-square test was used to analyzed the relationship between FBXW7 expression and clinicopathological characteristics. OS curves were calculated according to Kaplan-Meier method and log-rank test was used for comparing the survival distributions. Univariate and multivariate analyses were based on the cox proportional hazards regression model. All statistical tests were two-sided. P value less than 0.05 was considered statistically significant.

Results

FBXW7 mRNA expression in 24 paired gastric adenocarcinomas and noncancerous gastric tissues

FBXW7 mRNA expression levels in gastric adenocarcinomas and paired noncancerous gastric tissue in 24 patients were examined by quantitative real time-PCR. 18 s was used as an internal control. A scatter dot plot for mRNA relative expression levels is provided in Fig. 1, and shows generally low transcript levels of FBXW7 in the adenocarcinomas compared to control tissue (P = 0.0029).
Fig. 1

FBXW7 mRNA expression is decreased in paired cancerous and noncancerous tissue in 24 gastric adenocarcinoma patients. (P = 0.0029)

Correlation of FBXW7 expression with clinicopathological features in 546 gastric adenocarcinomas. To confirm FBXW7 expression, we performed an immunohistochemistry (IHC) study evaluating all 546 GC samples. Representative immunostains of FBXW7 scored as 0, 1, 2 and 3 are shown in Fig. 2.
Fig. 2

FBXW7 protein expression in gastric adenocarcinoma tissue sample: immunohistochemical representative images of FBXW7 expression scoring as 0, 1, 2 and 3. Images of 40X,100X, 200X AND 400X were showed in Fig. 2

Correlation of FBXW7 expression with clinicopathological features was analyzed and is shown in Table 1. Tumor size (P = 0.001), differentiation (P = 0.001), nodal stage (p = 0.040) and vessel invasion (P = 0.003) were found to be significantly different between high and low FBXW7 expression (P = 0.001). However, no significant differences were found regarding age, gender, depth of tumor and nerve invasion. FBXW7 expression was significantly associated with prognosis in our gastric cancer cohort. The overall survival curve of 546 GC patients is shown in Fig. 3, which demonstrates low FBXW7 expression correlates with poorer prognosis. Furthermore, a significant difference was found between high and low FBXW7 expression groups and corresponding OS in Stage III patients (n = 263). This difference was not seen in Stage I or II patients.
Table 1

Correlation of FBXW7expression and clinicopathological characteristics in 546 gastric adenocarcinoma patients

 

Number

FBWX7 low expression

FBWX7 high expression

P-Value

Age

   

0.182

  ≤ 60

253

118 (46.6%)

135 (53.4%)

 

  > 60

293

120 (41.0%)

173 (59.0%)

 

Gender

   

0.473

 Male

351

149 (42.5%)

202 (57.5%)

 

 Female

195

89 (45.6%)

106 (54.4%)

 

Tumor size

   

0.001*

  ≤ 5 cm

348

133 (38.2%)

215 (61.8%)

 

  > 5 cm

198

105 (53.0%)

93 (47.0%)

 

Histological grade

   

0.001*

 Well

16

5 (31.3%)

11 (68.7%)

 

 Moderate

140

44 (31.4%)

96 (68.6%)

 

 Poor

390

189 (48.5%)

201 (51.5%)

 

Depth of tumor (pT)

    

 T1

85

37 (43.5%)

48 (56.5%)

0.256

 T2

76

27 (35.5%)

49 (64.5%)

 

 T3

149

61 (40.9%)

88 (59.1%)

 

 T4

236

113 (47.9%)

123 (52.1%)

 

Nodal stage (pN)

   

0.040*

 N0

207

91 (44.0%)

116 (56.0%)

 

 N1

100

32 (32.0%)

68 (68.0%)

 

 N2

107

48 (44.9%)

59 (55.1%)

 

 N3

132

67 (50.8%)

65 (49.2%)

 

Vessel invasion

   

0.003*

 Negative

444

180 (40.5%)

264 (59.5%)

 

 Positive

102

58 (56.9%)

44 (43.1%)

 

Nerve invasion

   

0.148

 Negative

479

203 (42.4%)

276 (57.6%)

 

 Positive

67

35 (52.2%)

32 (47.8%)

 

*Statistical significant (P < 0.05)

Fig. 3

The overall survival curve of 546 GC patients demonstrated Low FBXW7 expression leads to poorer prognosis (P = 0.019). OS of stage III patients shows a significant difference between high and low FBXW7 expression groups (P = 0.004).OS of patients of stage I and stage II did not show a difference between the two groups

Correlation between FBXW7 expression and chemotherapy outcome in advanced stage gastric adenocarcinoma

All 546 patients received a radical gastrectomy. Among which, 118 and 428 of the patients were diagnosed as early (Stage I) and advanced (Stage II or III) stages respectively. According to the 7thAJCC edition, these 428 advanced stage patients were classified into Stages II and III based on the post-operational pathologic diagnosis. Amongst the advanced stage cases, 81 patients declined chemotherapy. The OS curves of these advanced patients with or without chemotherapy are shown in Fig. 4. High FBXW7 expression was associated with improved survival for those who received chemotherapy (P = 0.002, Kaplan-Meier log rank test).
Fig. 4

The overall survival curve of 347 advanced GC patients with postoperative chemotherapy show slow FBXW7 expression leads to worse chemotherapeutic outcome (P = 0.002). OS of 81 advanced patients without chemotherapy did not show a difference between the two groups

Subsequently, 347 patients received postoperative adjuvant chemotherapy. The chemotherapeutic regimens were primary floxuridine-based, with or without platinum, paclitaxel or anthracycline. Among them, 84 patients’ regimens included paclitaxel, 66 patients included anthracycline and 261 patients included platinum. The OS curves showed some significant prognostic correlation between different types of chemotherapeutics and high versus low FBXW7 expression (Fig. 5). The Kaplan-Meier log rank test demonstrated that high FBXW7 patients respond to paclitaxel and platinum better than low FBXW7 patients (P = 0.007 and P = 0.009 respectively). There was no significant difference between the two groups treated by anthracycline (P = 0.1565).
Fig. 5

FBXW7 expression correlates with outcome of different chemotherapeutics: a Low FBXW7 expression was associated with poor prognosis in patients chemotherapy with or without platinum, especially for 261 patients treated with platinum (P = 0.009 vs 0.044). b Low FBXW7 expression was associated with poor prognosis in patients chemotherapy with or without paclitaxel, especially for 81 patients treated with paclitaxel (P = 0.007 vs 0.033). c OS curve of 67 patients treated with anthracycline did not show a stratistical difference between the two groups

Univariate and multivariate analyses in advanced gastric adenocarcinoma

Univariate and multivariate Cox proportional hazards model analyses were performed on the clinicopathologic database of the 428 advanced stage patients to evaluate the prognostic parameters associated with overall survival (Table 2). According to the results of the univariate analyses, FBXW7 expression, tumor size, tumor differentiation, T stage, N stage, vessel invasion, nerve invasion and chemotherapy were significantly associated with overall survival. Furthermore, FBXW7 expression, tumor size and N stage were included in a multivariate Cox regression analysis to adjust for the covariates and were confirmed as independent prognostic factors.
Table 2

Univariate & multivariate analyses of prognosis parameters for OS in 347 advanced gastric cancer patients

 

Univariate analysis

Multivariate analysis

Prognostic parameter

RR

95% CI

P value

RR

95% CI

P value

FBXW7 (low vs.high)

0.688

0.527–0.899

0.006*

0.622

0.501–0.875

0.004*

Age (<60 vs. ≥60)

1.441

0.870–1.494

0.340

1.008

0.822–1.440

0.557

Gender (male vs. female)

0.942

0.712–1.246

0.674

0.979

0.734–1.306

0.887

Size (≤5 cm vs. >5 cm)

1.994

1.522–2.612

0.000*

1.539

1.156–2.048

0.003*

Tumor differentiation (well/moderate vs. poor)

1.426

1.406–1.945

0.025*

0.922

0.665–1.280

0.629

T stage (T2 vs. T3/T4)

3.104

2.253–4.277

0.000*

1.504

0.948–2.385

0.083

N stage (absent vs. present)

1.701

1.494–1.936

0.000*

1.404

1.158–1.701

0.001*

Vessel invasion (absent vs. present)

2.115

1.555–2.876

0.000*

1.372

0.975–1.931

0.070

Nerve invasion (absent vs. present)

1.819

1.292–2.561

0.001*

1.183

0.813–1.722

0.380

Chemotherapy (with or without)

0.707

0.509–0.982

0.038*

0.793

0.562–1.119

0.187

*Statistical significant (P < 0.05)

Discussion

In this study, we demonstrated that low level FBXW7 expression is associated with cancer progression and poor prognosis using a large database in gastric cancer. While similar conclusions have been noted in several other types of malignancies, this is the first large cohort study reported in gastric cancer. Moreover, we showed that FBXW7 may serve as a marker for chemotherapeutic sensitivity based on our analysis of corresponding clinical data.

It has been reported that low FBXW7 expression is associated with tumor progression in a diverse array of malignancies including breast, endometrial, ovarian, and pancreatic cancers as well as T-cell acute lymphoblastic leukemia [13, 14, 17]. In our study, gastric cancers with low FBXW7 expression was associated with cancer progression and worse prognosis. FBXW7 is a tumor suppressor that regulates degradation of oncogene proteins such as MYC, cyclin E, Notch, and MCL1 [18]. Yakobori found that FBXW7 mRNA expression level was associated with tumor size, lymphatic metastasis and prognosis in gastric cancer [16]. Our study also found a similar link with prognostic outcome, and further expanded on this by evaluating FBXW7 protein expression. FBXW7 regulates expression of various oncoproteins, but the specific targets and related pathways are not clear in gastric cancer. Yokobori also confirmed that down regulation of Fbxw7 gene expression by RNA interference can lead to c-Myc and cyclin-E accumulation and increased proliferation of gastric cancer cells. C-Myc plays an important role in mitogenesis and cell growth. Cyclin E is a key molecule in cell cycle regulation. Accordingly, both c-Myc and cyclin-E also show disordered expression in gastric cancer tissue [10].

Recently, an association between FBXW7 and chemotherapeutic sensitivity has been noted in several malignancies [19]. Our study shows by IHC data analysis that high FBXW7 expression is linked to an improved response to chemotherapy. However, the anthracycline treatment cohort does not show a similar correlation. Docetaxel, an analogue of paclitaxel, has been widely used in the treatment of advanced and late stage gastric cancer [20, 21]. Wertz found that a pro-survival protein,MCL1, is a crucial regulator of apoptosis triggered by antitubulin chemotherapeutics [22]. The degradation of MCL1 is blocked in patient-derived non-small cell lung cancer tumor cells that either lack FBXW7 or have loss-of-function mutations in FBXW7, in turn conferring resistance to antitubulin agents and promoting chemotherapeutic-induced polyploidy. This may be a mechanism by which docetaxel resistance occurs in gastric cancer. A correlation between cisplatin resistance and FBXW7 expression has also been indirectly reported by Zhou and colleagues [23]. They found MiR-223 promotes cisplatin resistance in human gastric cancer cells via regulation of the cell cycle by targeting FBXW7. Upregulation of FBXW7 partially reverses the effect of miR-223 mimic in 7901/DDP cells, demonstrating FBXW7 plays a crucial role in platinum treatment resistance. Furthermore, Kojiro reported miR-223 regulates FBXW7 leading to trastuzumab-resistance in Her-2 positive GC cells [24]. Overall, these studies suggest that FBXW7 may play an important role in chemotherapy resistance in cancers including gastric cancer.

Conclusions

In conclusion, we have identified low FBXW7 expression as a potential powerful marker of poor prognosis in patients with gastric adenocarcinoma. Furthermore, in view of the different chemotherapeutics outcomes found in this large database study, FBXW7 may serve as an important predictor in chemotherapeutic responses. However, there are still more studies need to be done to confirm FBXW7’s effectiveness in predicting the responses in specific chemotherapeutic regimen.

Abbreviations

FBXW7: 

F-box and WD repeat domain-containing7

GC: 

Gastric adenocarcinoma

IHC: 

Immunohistochemistry

MDR: 

Multidrug resistance

OS: 

Overall survival

PBS: 

Phosphate buffer solution

qRT-PCR: 

Quantitative reverse transcription PCR

SCF: 

Skp-Cullin1-F-box

Declarations

Funding

This work was supported by the Shanghai Science and Technology Committee Scientific Fund (project ID: 13ZR1425200).

Availability of data and materials

All summarized data generated or analysed during this study is included in this published article and its supplementary information files such as the figures and the tables, but we are not able to offer more raw data due to patient confidentiality.

Authors’ contributions

MRL made substantial contributions to draft the manuscript and revise it critically for important intellectual content; CCZ made substantial contributions to analysis and interpretation of data, involved in drafting the manuscript. TLL been involved in drafting the manuscript and revising it critically for important intellectual content; YQZ made contributions to performing experiments and analyzing and interpreting data. JX made substantial contributions to conception and design, and analysis and interpretation of data. EHZ made substantial contributions to conception and design, and analysis and interpretation of data. GZ made substantial contributions to conception and design. All authors have read and approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This project was approved by The Ethics Committee of RenJi Hospital, Shanghai JiaoTong University, School of Medicine for the use of samples. Verbal informed consents were obtained from all patients before study inclusion.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Gastrointestinal Surgery, RenJi Hospital, School of Medicine, Shanghai Jiao Tong University

References

  1. Alberts SR, et al. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003;14 Suppl 2:ii31–36.PubMedGoogle Scholar
  2. Liu L, et al. MiR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1α regulation. Oncogenesis. 2016;5:e224. doi:10.1038/oncsis.2016.35.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Roth AD. Chemotherapy in gastric cancer: a never ending saga. Ann Oncol. 2003;14(2):175–7.View ArticlePubMedGoogle Scholar
  4. Choi JH, et al. Expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer. 2002;86(10):1578–85.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Lorenzi F, et al. Fbxw7-associated drug resistance is reversed by induction of terminal differentiation in murine intestinal organoid culture. Mol Ther Methods Clin Dev. 2016;3:16024. doi:10.1038/mtm.2016.24.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Grim JE, et al. Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol. 2012;32(11):2160–7.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6(5):369–81.View ArticlePubMedGoogle Scholar
  8. Mao JH, et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature. 2004;432(7018):775–9.View ArticlePubMedGoogle Scholar
  9. Tu K, et al. Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. Hepatol Res. 2012;42(9):904–10.View ArticlePubMedGoogle Scholar
  10. Onoyama I, et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med. 2007;204(12):2875–88.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Chen MC, et al. Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIalpha degradation in hepatocellular carcinoma cells. Hepatology. 2011;53(1):148–59.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Inuzuka H, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471(7336):104–9.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Koo J, Yue P, et al. mTOR complex 2 stabilizes Mcl-1 protein by suppressing its glycogen synthase kinase 3-dependent and SCF-FBXW7-mediated degradation. Mol Cell Biol. 2015;35(13):2344–55. doi:10.1128/MCB.01525-14.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Calhoun ES, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol. 2003;163(4):1255–60.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Wang Z, et al. The two faces of FBW7 in cancer drug resistance. Bioessays. 2011;33(11):851–9.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Yokobori T, et al. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res. 2009;69(9):3788–94.View ArticlePubMedGoogle Scholar
  17. Jardim DL, et al. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One. 2014;9(2):e89388. doi:10.1371/journal.pone.0089388.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Mao JH, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499–502.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Yokobori T, et al. FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs. Mol Cancer Res. 2014;12(1):32–7.View ArticlePubMedGoogle Scholar
  20. Ozdemir N, et al. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. Cancer Chemother Pharmacol. 2014;74(6):1139–47.View ArticlePubMedGoogle Scholar
  21. Pernot S, et al. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. Gastric Cancer. 2014;17(2):341–7.View ArticlePubMedGoogle Scholar
  22. Wertz IE, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011;471(7336):110–4.View ArticlePubMedGoogle Scholar
  23. Zhou X, et al. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7. J Exp Clin Cancer Res. 2015;34:28.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Eto K, et al. The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. Int J Cancer. 2015;136(7):1537–45.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement